CO2020014514A2 - Composición farmacéutica tópica para el tratamiento de fisuras anales y hemorroides - Google Patents

Composición farmacéutica tópica para el tratamiento de fisuras anales y hemorroides

Info

Publication number
CO2020014514A2
CO2020014514A2 CONC2020/0014514A CO2020014514A CO2020014514A2 CO 2020014514 A2 CO2020014514 A2 CO 2020014514A2 CO 2020014514 A CO2020014514 A CO 2020014514A CO 2020014514 A2 CO2020014514 A2 CO 2020014514A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
hemorrhoids
treatment
topical pharmaceutical
anal fissures
Prior art date
Application number
CONC2020/0014514A
Other languages
English (en)
Inventor
Souza Teixeira Leonardo De
Faria Jeane Roberta Santana De
Castro Melo Nogueira Gílbia De
Mundim Iram Moreira
Rezeck Laura Moreira
Itapema Alves Carina Pimentel
Bellorio Karini Bruno
Fernandes Sarah Rodrigues
Itapema Alves Viviane Pimentel
De Mendonça Filho Robert Frederic Wooley
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of CO2020014514A2 publication Critical patent/CO2020014514A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

RESUMEN La presente invención se refiere a una composición farmacéutica tópica que va a usarse en la región anal para fisuras anales y hemorroides, incluyendo el periodo posoperatorio de hemorroidectomía. La composición farmacéutica comprende un dilatador anal, un polímero mucoadhesivo y un vehículo no acuoso. También se describe un método de fabricación de la composición farmacéutica.
CONC2020/0014514A 2018-04-25 2020-11-23 Composición farmacéutica tópica para el tratamiento de fisuras anales y hemorroides CO2020014514A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR102018008324-4A BR102018008324A2 (pt) 2018-04-25 2018-04-25 composição farmacêutica de uso tópico e processo de fabricação de composição farmacêutica de uso tópico
PCT/EP2019/060643 WO2019207059A1 (en) 2018-04-25 2019-04-25 Topical pharmaceutical composition for treatment of anal fissures and hemorrhoids

Publications (1)

Publication Number Publication Date
CO2020014514A2 true CO2020014514A2 (es) 2021-04-19

Family

ID=66290462

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0014514A CO2020014514A2 (es) 2018-04-25 2020-11-23 Composición farmacéutica tópica para el tratamiento de fisuras anales y hemorroides

Country Status (17)

Country Link
US (1) US11865207B2 (es)
EP (1) EP3784210B1 (es)
JP (1) JP2021522267A (es)
KR (1) KR20210005664A (es)
CN (1) CN112020349A (es)
AU (1) AU2019258677B2 (es)
BR (2) BR102018008324A2 (es)
CA (1) CA3098256C (es)
CL (1) CL2020002743A1 (es)
CO (1) CO2020014514A2 (es)
DK (1) DK3784210T3 (es)
EA (1) EA202092546A1 (es)
FI (1) FI3784210T3 (es)
LT (1) LT3784210T (es)
MX (1) MX2020011281A (es)
PT (1) PT3784210T (es)
WO (1) WO2019207059A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019229535A2 (en) 2018-06-01 2019-12-05 Druggability Technologies Ip Holdco Ltd. Topical amlodipine salts for the treatment of anorectal diseases
RU2733080C1 (ru) * 2019-12-13 2020-09-29 Александр Евгеньевич Баранников Фармакологическая композиция для лечения проктологических заболеваний (варианты).
CN112691104A (zh) * 2021-02-04 2021-04-23 刘泽陆 一种用于治疗痔疮的药物及其制备方法
CN115337258A (zh) * 2022-07-22 2022-11-15 上海奥全生物医药科技有限公司 一种盐酸地尔硫卓的药物组合物、制备方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118480A (en) * 1973-02-09 1978-10-03 Charles V. Stoelker Pharmaceutical preparation for treating hemorrhoids and anal fissures
JPS61212515A (ja) * 1985-03-16 1986-09-20 Taisho Pharmaceut Co Ltd 痔疾用軟膏
US6106856A (en) * 1994-03-09 2000-08-22 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Transdermal delivery of calcium channel blockers, such as nifedipine
GB9422571D0 (en) * 1994-11-09 1995-01-04 Whitehall Lab Ltd Haemorrihoidal compositions and method of use
EP1249238A3 (en) 1997-02-24 2003-03-26 S.L.A. Pharma AG Topical pharmaceutical composition comprising bethanechol
US20030114394A1 (en) * 2001-10-29 2003-06-19 Levine Howard L. Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US20080317679A1 (en) 2002-10-25 2008-12-25 Foamix Ltd. Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
US20040167479A1 (en) * 2003-02-20 2004-08-26 The Procter & Gamble Company Hemorrhoid treatment pad
KR100733028B1 (ko) * 2003-08-29 2007-06-28 사토 세이야쿠 가부시키가이샤 직장 투여용 제제
EP1848403B8 (en) * 2005-01-14 2010-05-19 Camurus Ab Topical bioadhesive formulations
WO2007003204A1 (en) 2005-07-06 2007-01-11 Mahmoud Timour Mohamed Radwan Topical formulation for the treatment of ano-rectal diseases
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CN1771981A (zh) * 2005-10-18 2006-05-17 夏运岳 一种痔疮膏
EP2432450B1 (en) * 2009-05-22 2019-07-31 Wyeth LLC Single-use, disposable strip for application of topical compositions
RO126996B1 (ro) * 2011-04-01 2013-03-29 Klm Group S.R.L. Cremă pentru tratamentul fisurilor anale şi procedeu de obţinere
WO2014127475A1 (en) 2013-02-19 2014-08-28 Hochman David Jonathan Therapeutic composition for the treatment perianal disorders
KR101847947B1 (ko) * 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
WO2016118040A1 (ru) * 2015-01-21 2016-07-28 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Гель, содержащий нифедипин и лидокаина гидрохлорид, его применение и способ приготовления с использованием нанотехнологий
WO2017117268A1 (en) * 2015-12-28 2017-07-06 Hybrid Medical, Llc Topical therapeutic formulations containing a calcium channel blocker, superoxide dismutase and emu oil

Also Published As

Publication number Publication date
BR102018008324A2 (pt) 2019-11-05
JP2021522267A (ja) 2021-08-30
MX2020011281A (es) 2020-11-13
EP3784210A1 (en) 2021-03-03
PT3784210T (pt) 2024-05-23
AU2019258677A1 (en) 2020-11-26
BR112020021572A2 (pt) 2021-01-19
WO2019207059A1 (en) 2019-10-31
KR20210005664A (ko) 2021-01-14
CA3098256C (en) 2024-05-14
CA3098256A1 (en) 2019-10-31
EA202092546A1 (ru) 2021-03-02
CL2020002743A1 (es) 2021-01-15
CN112020349A (zh) 2020-12-01
EP3784210B1 (en) 2024-03-13
FI3784210T3 (fi) 2024-06-13
DK3784210T3 (da) 2024-05-27
LT3784210T (lt) 2024-05-10
US20220151918A1 (en) 2022-05-19
US11865207B2 (en) 2024-01-09
AU2019258677B2 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
CO2020014514A2 (es) Composición farmacéutica tópica para el tratamiento de fisuras anales y hemorroides
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
UY37480A (es) Nuevos derivados de quinolina
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
MX2022008479A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
NI201500115A (es) Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
CO2020013876A2 (es) Nuevos derivados de quinolina
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
DOP2014000218A (es) Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné
MY193312A (en) Topical formulation for promoting wound healing
CR20210507A (es) Composición farmacéutica acuosa de anticuerpo anti-il17a y su uso
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
CO2018002428A2 (es) Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol
BR112019000878A2 (pt) absorvente interno.
BR112015014262A2 (pt) formulação farmacêutica, dispositivo adaptado para distribuição intranasal de uma formulação farmacêutica, método de tratamento de rinite alérgica, uso de uma formulação farmacêutica, e, método para o tratamento de condição inflamatória e/ou alérgica
PH12015502274B1 (en) Lozenge for treating a sore throat, hoarseness, and associated dry cough and for treating inflammatory diseases of the oral cavity and of the pharynx
CL2019002020A1 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer.
CL2020000859A1 (es) Derivados de ácido glucónico para ser usados en el tratamiento y/o prevención de infecciones microbianas.
AR109019A1 (es) Formas de dosis orales en bajas dosis para el tratamiento de enfermedades
BR112018075983A2 (pt) composições compreendendo timolol e um agente anti-inflamatório
CL2021002430A1 (es) Formulación de tableta vaginal